Evaluation of safety, side effects and how the drug CHF6467 administrated via intranasal route is absorbed, modified and removed in healthy subjects.
CLI-06467AC1-02
Phase 1 other active
Quick answer
Evaluation of safety, side effects and how the drug CHF6467 administrated via intranasal route is absorbed, modified and removed in healthy subjects. for Neonatal Hypoxic-Ischemic Encephalopathy (HIE), Neonatal Hypoxic-Ischemic Encephalopathy (HIE) is a Phase 1 program (other) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Chiesi Farmaceutici S.p.A
- Indication
- Neonatal Hypoxic-Ischemic Encephalopathy (HIE), Neonatal Hypoxic-Ischemic Encephalopathy (HIE)
- Phase
- Phase 1
- Modality
- other
- Status
- active